25I-NBOMe, also known as 2C-I-NBOMe, Cimbi-5, and shortened to "25I", is a psychedelic drug of the phenethylamine, 2C, and NBOMe (25-NB) families. Since 2010, it has circulated in the recreational drug scene, often misrepresented as LSD. It is the most well-known member of the 25-NB family and the earliest member to be encountered as a novel recreational drug.
Street and media nicknames for this drug include "N-Bomb", "Solaris", "Smiles", and "Wizard", although the drug is frequently fraudulently sold as LSD.
Due to its physical effects and risk of overdose, there have been multiple deaths attributed to the drug. Its long-term toxicity is unknown due to lack of existing research.
25I-NBOMe was first described in 2000. It was first encountered as a novel recreational drug in 2010, and by 2012, NBOMes like 25I-NBOMe had surpassed other major psychedelics like LSD and psilocybin-containing mushrooms in popularity, at least for a time. 25I-NBOMe became a controlled substance in the United States in 2013.
Harm Reduction
25I-not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. Tolerance to the effects of 25I-almost immediately after ingestion. After that,12 weeks...
The onset arrives like a switch being thrown. Within ten to fifteen minutes, the bitter chemical burn in the mouth is joined by a surging wave of stimulant energy that pours through the body with startling force. The heart hammers. Blood pressure spikes. Vasoconstriction grips the extremities -- fingers and toes go cold and pale, and there is a tightness in the chest that demands conscious attention to breathing. The visual field begins to fragment and reorganize itself before the body has had time to adjust to the physical onslaught. This is not a substance that eases you in.
By thirty minutes, the visual effects have reached an intensity that is genuinely difficult to overstate. Every surface in the environment erupts with dense, intricate, rapidly shifting geometric patterns -- crystalline fractals, spiraling mandalas, tessellating grids of impossible complexity, all rendered in hyper-saturated neon colors that seem to generate their own light. The world looks as though it has been rebuilt from scratch using only mathematics and fluorescent pigment. Afterimages are intense and persistent, creating overlapping layers of visual information that can make navigation difficult. Faces morph and distort dramatically. The visual intensity at moderate doses of 25I-NBOMe exceeds what most other psychedelics achieve at any dose.
The body load is the defining challenge of the experience. Vasoconstriction is persistent and can become genuinely alarming -- numbness and tingling in the extremities, cold hands and feet, a tight band of pressure around the chest. Nausea comes in powerful waves. Jaw clenching is severe and involuntary. The stimulant energy is enormous and relentless, making stillness feel impossible while also making coordinated movement difficult. Despite all this, the headspace remains curiously shallow relative to the sensory bombardment. Thoughts are rapid and somewhat disorganized but lack the profound ego dissolution or emotional depth of classical psychedelics. The experience is more spectacle than journey -- a dazzling, physically punishing light show playing out across the surface of consciousness.
The peak lasts three to four hours and the total experience extends six to ten hours. The descent is slow and often uncomfortable, with residual vasoconstriction and stimulant effects persisting long after the visual fireworks have dimmed. The aftermath can include headache, muscle soreness from sustained tension, exhaustion, and a flat, depleted mood. Recovery to full baseline may take a day or more. The overall character is one of overwhelming sensory power delivered at a significant physical cost -- an experience that inspires awe and caution in equal measure.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(17)
Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
Muscle tension— Persistent partial contractions or tightening of muscles that produces uncomfortable stiffness, cram...
Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Cognitive & Perceptual Effects
Visual(20)
After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
Pharmacology
25I-NBOMe has efficacy at the 5-HT2A receptor where it acts as a Full agonist.
This substance came to media attention in early 2012 after a cluster of seven non-fatal overdoses with the drug were reported in or around Richmond, Virginia. As of May 2013, 25I-NBOMe has reportedly led to five overdose deaths in the United States. In June 2012, two teens in Grand Forks, North Dakota and East Grand Forks, Minnesota fatally overdosed on a substance that was allegedly 25I-NBOMe, resulting in lengthy sentences for two of the parties involved and a Federal indictment against the Texas-based online vendor.
A 21-year-old man from Little Rock, Arkansas died in October 2012 after taking a liquid drop of the drug nasally at a music festival. He was reported to have consumed caffeinated alcoholic beverages for "several hours" beforehand. It is unclear what other drugs he may have consumed, as autopsies usually do not test for the presence of research chemicals.
A man in Australia died from injuries sustained by running into trees and power poles while intoxicated by 25I-NBOMe.
A Brazilian 16-year-old died from overdose in April 2016.
The addition of 5-HTP can greatly increase the effects of 25i-NBOME and should be avoided.
It is strongly recommended that one use harm reduction practices when using this substance.
25I-not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 25I-almost immediately after ingestion. After that,12 weeks to be back at baseline (in the absence of further consumption). 25I-NBOMe presents cross-tolerance with Cross-all psychedelics, meaning that after the consumption of 25I-NBOMe all psychedelics will have a reduced effect.
Overdose
In September 2014, the European Council decided that 25I-NBOMe shall be subjected by the Member States to control measures and criminal penalties by October 2, 2015.
Australia: Possession, production and sale is illegal.
Austria: Since June 26, 2019, 25I-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
Canada: 25I-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
Denmark: 25I-NBOMe is controlled by the generic classification of phenethylamines in the Executive Order on Euphoriant Substances.
Germany: 25I-NBOMe is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Finland: 25I-NBOMe is controlled under the Medicines Act (395/87) as of March 15, 2013.
Hungary: 25I-NBOMe falls within the generic definition of phenethylamines in Schedule C of Government Decree 66/2012.
Israel: The drug was banned in 2012.
Italy: In Italy 25I-NBOMe is a Schedule 1 controlled substance, meaning it's illegal in this state.
Japan: 25I-NBOMe is a narcotic drug in Japan effective November 1st, 2015.
Latvia: 25I-NBOMe is a Schedule I controlled substance.
The Netherlands:** 25I-NBOMe is classified as a Lijst 1 (List 1) controlled substance under the Opiumwet (Opium Law).
New Zealand: 25I-NBOMe is a Schedule 2 controlled substance in New Zealand.
Norway: 25I-NBOMe is controlled by the generic scheduling of phenethylamines as of February 14, 2013.
Poland: 25I-NBOMe falls under the definition of a ‘substitution drug’ under the Act on Counteracting Drug Addiction and the Act on State Sanitary Inspection, 2010. As such its marketing and production is penalised with a fine (administrative sanctions).
Romania: In 2011, Romania banned all psychoactive substances, no matter what they really are.
Russia: Possession, production and sale is illegal.
Slovenia: 25I-NBOMe was included in a Decree amending the classification of illicit drugs (Official Gazette of RS No. 62/2013).
Sweden: 25I-NBOMe is classed as Schedule I.
Switzerland: 25I-NBOMe is a controlled substance specifically named under Verzeichnis D.
United Kingdom: 25I-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.
United States: On Nov 15, 2013, the DEA added 25I-NBOMe to Schedule I using their emergency scheduling powers, making it "temporarily" in Schedule I for 2 years.
25I-NBOMe, broken down and described (Disregard Everything I Say)
Detection Methods
Urine Detection
25I-NBOMe is not targeted by standard immunoassay-based urine drug screens. However, due to its phenethylamine backbone, there is a theoretical possibility of cross-reactivity with amphetamine immunoassays, though this has not been consistently reported in clinical literature. Specialized LC-MS/MS methods developed for novel psychoactive substances can detect NBOMe compounds and their metabolites in urine for approximately 24 to 48 hours after ingestion, depending on dose and individual metabolism.
Blood and Serum Detection
Blood detection windows for 25I-NBOMe are relatively short. Peak plasma concentrations occur within 30 minutes to 2 hours depending on the route of administration (sublingual absorption is typical for NBOMe compounds). Blood concentrations fall below detectable thresholds within 6 to 16 hours for most methods. LC-MS/MS remains the only reliable analytical approach for serum detection, as the doses involved (typically hundreds of micrograms to low milligrams) produce low absolute concentrations.
Standard Drug Panel Inclusion
25I-NBOMe is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. It is not specifically targeted by any routine workplace or clinical immunoassay. While some structural similarity to amphetamines exists, cross-reactivity on amphetamine panels is inconsistent and cannot be relied upon for either detection or exclusion. Identification requires specific testing at a reference laboratory equipped for novel psychoactive substance analysis.
Confirmatory Methods
Definitive identification of 25I-NBOMe requires LC-MS/MS or high-resolution mass spectrometry (HRMS). GC-MS can also be employed but may require derivatization due to the thermal lability of NBOMe compounds. Reference standards are necessary for quantitative confirmation. Forensic and clinical toxicology laboratories that maintain novel psychoactive substance panels are the only facilities reliably capable of this analysis.
Reagent Testing (Harm Reduction)
Reagent testing is critically important for NBOMe compounds due to their significantly higher toxicity profile compared to classical psychedelics. The Ehrlich reagent shows NO reaction with 25I-NBOMe, which is the single most important distinguishing test: any substance sold as a psychedelic that fails to turn purple with Ehrlich may be an NBOMe compound rather than LSD or a tryptamine. The Marquis reagent produces variable results depending on the specific NBOMe compound, ranging from no reaction to green or brown color changes. The Mecke reagent may produce a brown or dark green reaction. For harm reduction purposes, always testing with Ehrlich first is essential. The absence of a purple Ehrlich reaction is a strong warning sign that the substance is not a lysergamide or tryptamine and may be a potentially dangerous NBOMe compound.
Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers
Showing 63 key interactions out of 84 total.
History
The history of 25I-NBOMe is intertwined with the broader story of psychedelic research, which has oscillated between periods of intense scientific interest and strict prohibition.
Like many psychedelic compounds, 25I-NBOMe was either synthesized in a laboratory setting or identified as a naturally occurring psychoactive substance through ethnobotanical research. The mid-20th century saw an explosion of interest in psychedelic compounds, with researchers exploring their potential applications in psychotherapy, creativity enhancement, and the study of consciousness.
The political and cultural backlash of the late 1960s and early 1970s led to the criminalization of most psychedelic substances, effectively halting legitimate research for decades. The resurgence of psychedelic research beginning in the 2000s — often called the "psychedelic renaissance" — has renewed scientific interest in this class of compounds, with clinical trials exploring applications in treatment-resistant depression, PTSD, end-of-life anxiety, and addiction.
25I-NBOMe exists within this broader pharmacological and cultural context, with its specific history shaped by its date of discovery, legal status, availability, and unique pharmacological profile.
Harm Reduction
25I-not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 25I-almost immediately after ingestion. After that,12 weeks to be back at baseline (in the absence of further consumption). 25I-NBOMe presents cross-tolerance with Cross-all psychedelics, meaning that after the consumption of 25I-NBOMe all psychedelics will have a reduced effect.
Overdose
In September 2014, the European Council decided that 25I-NBOMe shall be subjected by the Member States to control measures and criminal penalties by October 2, 2015.
Australia: Possession, production and sale is illegal.
Austria: Since June 26, 2019, 25I-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
Canada: 25I-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
Denmark: 25I-NBOMe is controlled by the generic classification of phenethylamines in the Executive Order on Euphoriant Substances.
Germany: 25I-NBOMe is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Finland: 25I-NBOMe is controlled under the Medicines Act (395/87) as of March 15, 2013.
Hungary: 25I-NBOMe falls within the generic definition of phenethylamines in Schedule C of Government Decree 66/2012.
Israel: The
Toxicity & Safety
Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens
Short-term as well as long-term damage of NBOMes have been occasionally tied to serious physical and mental problems on seemingly random people, including memory and speech difficulties, heart problems, HPPD and in some cases Anxiety and PTSD, from particularly difficult experiences.
25I-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The LD50 has not yet been determined although it is potentially fatal at heavy dosages. PsychonautWiki advises that due to 25I-NBOMe's extreme potency it should not be insufflated as this method of administration appears to have led to several deaths in the past year.
This substance came to media attention in early 2012 after a cluster of seven non-fatal overdoses with the drug were reported in or around Richmond, Virginia. As of May 2013, 25I-NBOMe has reportedly led to five overdose deaths in the United States. In June 2012, two teens in Grand Forks, North Dakota and East Grand Forks, Minnesota fatally overdosed on a substance that was allegedly 25I-NBOMe, resulting in lengthy sentences for two of the parties involved and a Federal indictment against the Texas-based online vendor.
A 21-year-old man from Little Rock, Arkansas died in October 2012 after taking a liquid drop of the drug nasally at a music festival. He was reported to have consumed caffeinated alcoholic beverages for "several hours" beforehand. It is unclear what other drugs he may have consumed, as autopsies usually do not test for the presence of research chemicals.
A man in Australia died from injuries sustained by running into trees and power poles while intoxicated by 25I-NBOMe.
A Brazilian 16-year-old died from overdose in April 2016.
The addition of 5-HTP can greatly increase the effects of 25i-NBOME and should be avoided.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
25I-NBOMe is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 25I-NBOMe is built almost immediately after ingestion. After that, it takes about 1 week for the tolerance to be reduced to half and 2 weeks to be back at baseline (in the absence of further consumption). 25I-NBOMe presents cross-tolerance with all psychedelics, meaning that after the consumption of 25I-NBOMe all psychedelics will have a reduced effect.
Overdose
Due to the very high potency and seemingly unpredictable effects the margin between a normal and an overdose of NBOMe compounds is extremely small when compared to many other substances. The exact toxic dose is unclear since it seems to depend a lot on personal physiology, rather than predominantly dose. However, various anecdotal reports suggest that dangerous side effects begin to appear when exceeding 1000 μg and it possibly becoming lethal for the more sensitive people at roughly 2000 μg. Reports of other people surviving much higher doses, sometimes even without any major side effects have been documented as well.
There is also the uncertainty of dosage on blotter paper since it is rather difficult to lay such an exact dosage. Insufflating, vaporizing or drinking tinctures of this substance is highly discouraged because of this and has been tied to many documented deaths. One study found that 25I‐NBOMe and 25C‐NBOMe blotter papers contained 'hotspots' with higher quantities of the drug, implying an inherent risk of overdosing.
The overdose effects of NBOMes are typically a dangerously high heart rate, blood pressure, hyperthermia and significant vasoconstriction also accompanied by confusion, delusions, panic attacks, aggressive behavior, numbness or pain, amnesia and often seizures. The risks in an overdose include anything from organ failure to cardiac arrest and death. There are also multiple reports of people lethally injuring themselves or falling to death. Benzodiazepines or antipsychotics can help with the psychological effects during an overdose although medical attention should always be called in even a possible overdose of 25I-NBOMe.
Dangerous interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
Due to the highly unpredictable nature of the NBOMe series, it is generally advised to avoid mixing them with other psychoactive substances.
2C-T-X - The 2C-T-X phenethylamines can be unpredictable in their interactions and the NBOMes are known to be unpredictable even alone. As a result, this combination should be avoided.
5-MeO-xxt - The 5-MeO tryptamines can be unpredictable in their interactions and the NBOMes are known to be unpredictable even alone. As a result, this combination should be avoided.
Amphetamines - Amphetamines and NBOMes both provide considerable stimulation. When combined they can result in tachycardia, hypertension, vasoconstriction and, in extreme cases, heart failure. The anxiogenic and focusing effects of stimulants are also not good in combination with psychedelics as they can lead to unpleasant thought loops. NBOMes are known to cause seizures and stimulants can increase this risk.
aMT
Caffeine - Caffeine can bring out the natural stimulation from psychedelic drugs to make it uncomfortable. High doses can cause anxiety which is hard to handle while tripping.
Cannabis - Cannabis has an unexpectedly strong and unpredictable synergy with the effects of psychedelics. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid over intake.
Cocaine - Cocaine and NBOMes both provide considerable stimulation. When combined they can result in severe vasoconstriction, tachycardia, hypertension, and in extreme cases heart failure.
Lithium - Lithium is commonly prescribed in the treatment of [https://en.wikipedia.org/wiki/Bipolar_disorder bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
MAOIs - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably.
MXE - As an NMDA antagonist, MXE potentiates NBOMes which can be unpleasantly intense.
Tramadol - Tramadol is well known to lower seizure threshold and NBOMes have also shown a tendency to cause severe seizures
Addiction Potential
not habit-forming
Overdose Information
LD50potentially fatal at heavy dosages. PsychonautWiki advises that due to 25I-NBOMe's extreme potency it should not be insufflated as this method of administration appears to have led to several deaths in the past year.
This substance came to media attention in early 2012 after a cluster of seven non-fatal overdoses with the drug were reported in or around Richmond, Virginia. As of May 2013, 25I-NBOMe has reportedly led to five overdose deaths in the United States. In June 2012, two teens in Grand Forks, North Dakota and East Grand Forks, Minnesota fatally overdosed on a substance that was allegedly 25I-NBOMe, resulting in lengthy sentences for two of the parties involved and a Federal indictment against the Texas-based online vendor.
A 21-year-old man from Little Rock, Arkansas died in October 2012 after taking a liquid drop of the drug nasally at a music festival. He was reported to have consumed caffeinated alcoholic beverages for "several hours" beforehand. It is unclear what other drugs he may have consumed, as autopsies usually do not test for the presence of research chemicals.
A man in Australia died from injuries sustained by running into trees and power poles while intoxicated by 25I-NBOMe.
A Brazilian 16-year-old died from overdose in April 2016.
The addition of 5-HTP can greatly increase the effects of 25i-NBOME and should be avoided.
It is strongly recommended that one use harm reduction practices when using this substance.
25I-not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 25I-almost immediately after ingestion. After that,12 weeks to be back at baseline (in the absence of further consumptio
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
In September 2014, the European Council decided that 25I-NBOMe shall be subjected by the Member States to control measures and criminal penalties by October 2, 2015.
Australia: Possession, production and sale is illegal.
Austria: Since June 26, 2019, 25I-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
Canada: 25I-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
Denmark: 25I-NBOMe is controlled by the generic classification of phenethylamines in the Executive Order on Euphoriant Substances.
Germany: 25I-NBOMe is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Finland: 25I-NBOMe is controlled under the Medicines Act (395/87) as of March 15, 2013.
Hungary: 25I-NBOMe falls within the generic definition of phenethylamines in Schedule C of Government Decree 66/2012.
Israel: The drug was banned in 2012.
Italy: In Italy 25I-NBOMe is a Schedule 1 controlled substance, meaning it's illegal in this state.
Japan: 25I-NBOMe is a narcotic drug in Japan effective November 1st, 2015.
Latvia: 25I-NBOMe is a Schedule I controlled substance.
The Netherlands:** 25I-NBOMe is classified as a Lijst 1 (List 1) controlled substance under the Opiumwet (Opium Law).
New Zealand: 25I-NBOMe is a Schedule 2 controlled substance in New Zealand.
Norway: 25I-NBOMe is controlled by the generic scheduling of phenethylamines as of February 14, 2013.
Poland: 25I-NBOMe falls under the definition of a ‘substitution drug’ under the Act on Counteracting Drug Addiction and the Act on State Sanitary Inspection, 2010. As such its marketing and production is penalised with a fine (administrative sanctions).
Romania: In 2011, Romania banned all psychoactive substances, no matter what they really are.
Russia: Possession, production and sale is illegal.
Slovenia: 25I-NBOMe was included in a Decree amending the classification of illicit drugs (Official Gazette of RS No. 62/2013).
Sweden: 25I-NBOMe is classed as Schedule I.
Switzerland: 25I-NBOMe is a controlled substance specifically named under Verzeichnis D.
United Kingdom: 25I-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.
United States: On Nov 15, 2013, the DEA added 25I-NBOMe to Schedule I using their emergency scheduling powers, making it "temporarily" in Schedule I for 2 years.
25I-NBOMe is frequently sold as LSD. The telltale signs are a strong bitter metallic taste that numbs your tongue and mouth. If a blotter tastes noticeably bitter, spit it out immediately. Real LSD is tasteless or has only a faint paper taste.
always_test_blotters · Mar 4
An Ehrlich reagent test kit is essential if you are buying blotter psychedelics. 25I-NBOMe will not react with Ehrlich reagent, while LSD will turn purple. This simple 2-dollar test can literally save your life.
ehrlich_saves_lives · Mar 4
25I-NBOMe has been linked to multiple deaths and hospitalizations. It can cause seizures, hyperthermia, and cardiovascular emergencies even at doses only slightly above common recreational levels. The margin of safety is very narrow compared to classical psychedelics.
seizure_risk_info · Mar 4
Have a trip sitter present, ideally someone with psychedelic experience. They should remain calm and reassuring without being intrusive. A good sitter can make the difference between a challenging experience and a genuine crisis.
ElectrolyteEd · Mar 4
If you knowingly choose to take 25I-NBOMe, never take more than one blotter tab and never insufflate it. The difference between a recreational dose and a medical emergency can be as small as a few hundred micrograms. Dose-response curves for NBOMe compounds are extremely steep.
half_tab_max · Mar 4
Significant vasoconstriction is common with 25I-NBOMe. If you experience numbness, blue or cold extremities, severe headache, or chest pain, seek medical attention immediately. Do not take vasoconstrictive substances like stimulants alongside NBOMe compounds.
Synthetic hallucinogen 25I-NBOMe, also known as 2C-I-NBOMe, Cimbi-5, and shortened to "25I", is a psychedelic drug of the phenethylamine, 2C, and NBOMe (25-NB) families. Since 2010, it has circulated in the recreational drug scene, often misrepresented as LSD. It is the most well-known member of the
What are the effects of 25I-NBOMe?
The onset arrives like a switch being thrown. Within ten to fifteen minutes, the bitter chemical burn in the mouth is joined by a surging wave of stimulant energy that pours through the body with startling force. The heart hammers. Blood pressure spikes. Vasoconstriction grips the extremities -- fin
Is 25I-NBOMe addictive?
not habit-forming
What are the risks of 25I-NBOMe?
Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens Short-term as well as long-term damage of NBOMes have been occasionally tied to serious physical and mental problems on seemingly random people, including memory and speech difficulties, heart
How long does 25I-NBOMe last?
The total duration of 25I-NBOMe via insufflated is 4 hours to 6 hours. Onset typically occurs within 5 minutes to 10 minutes. Peak effects last 1 hour to 2 hours.
Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
Frame rate suppression— Perception of visual motion as choppy discrete frames rather than smooth continuous flow, resembling...
Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
Magnification— A visual distortion in which objects appear larger or closer than they actually are, as though one's...
Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
Recursion— The visual field begins to repeat and nest within itself in a self-similar, fractal-like manner, as ...
Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(16)
Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Multi-sensory(2)
Sensory overload— An overwhelming flood of sensory information that exceeds the brain's ability to process, creating a...
Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(3)
Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
